GlobeNewswire: Opiant Pharmaceuticals, Inc. Contains the last 10 of 158 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:10:06ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/02/07/2603491/0/en/Opiant-Pharmaceuticals-Announces-CFIUS-Approval-for-Proposed-Acquisition-by-Indivior-PLC.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC2023-02-07T21:01:00Z<![CDATA[SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV).]]>https://www.globenewswire.com/news-release/2023/02/06/2602020/0/en/Opiant-Pharmaceuticals-Announces-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Proposed-Acquisition-by-Indivior-PLC.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC2023-02-06T13:00:00Z<![CDATA[SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV).]]>https://www.globenewswire.com/news-release/2023/01/19/2592131/0/en/Opiant-Pharmaceuticals-Announces-FDA-Acceptance-and-Priority-Review-of-NDA-for-OPNT003-Nasal-Nalmefene-for-Opioid-Overdose.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose2023-01-19T21:05:00Z<![CDATA[SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for OPNT003, nasal nalmefene, Opiant’s product candidate for the treatment of opioid overdose.]]>https://www.globenewswire.com/news-release/2022/06/08/2459192/0/en/Opiant-Pharmaceuticals-and-Aptar-Pharma-Expand-Long-Term-Collaboration-for-the-Manufacture-of-Unidose-Nasal-Spray-for-OPNT003-Nasal-Nalmefene.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene2022-06-08T20:05:00Z<![CDATA[Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003 Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003]]>https://www.globenewswire.com/news-release/2022/06/01/2454719/0/en/Opiant-Pharmaceuticals-Initiates-Rolling-Submission-of-New-Drug-Application-to-U-S-Food-and-Drug-Administration-for-OPNT003-Nasal-Nalmefene-for-the-Treatment-of-Opioid-Overdose.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose2022-06-01T20:05:00Z<![CDATA[SANTA MONICA, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced the filing of the first module of its New Drug Application (NDA) for OPNT003, nasal nalmefene, for the treatment of opioid overdose. The module was submitted pursuant to a rolling submission, as agreed with the U.S. Food and Drug Administration (FDA) during a pre-NDA meeting. As communicated previously, the Company expects to complete the submission of the NDA using the 505(b)(2) pathway in the second half of 2022.]]>https://www.globenewswire.com/news-release/2022/05/20/2447922/0/en/Opiant-Pharmaceuticals-to-Hold-Virtual-2022-Annual-Shareholder-Meeting-on-Tuesday-June-14-2022-at-9-00am-PDT.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT2022-05-20T20:05:00Z<![CDATA[SANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The meeting will be held online only and will begin at 09:00 AM PDT on June 14, 2022, as previously scheduled. The matters to be voted on at the 2022 Annual Meeting, remain unchanged.]]>https://www.globenewswire.com/news-release/2022/05/10/2440187/0/en/Opiant-Pharmaceuticals-Announces-First-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update2022-05-10T20:01:00Z<![CDATA[SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a corporate update. Recent highlights include:]]>https://www.globenewswire.com/news-release/2022/05/03/2434482/0/en/Opiant-Pharmaceuticals-to-Report-First-Quarter-2022-Financial-Results-and-Host-Conference-Call-and-Webcast-on-May-10-2022.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 20222022-05-03T12:00:00Z<![CDATA[SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial markets close on Tuesday, May 10, 2022.]]>https://www.globenewswire.com/news-release/2022/04/27/2430661/0/en/Opiant-Pharmaceuticals-Announces-Positive-Topline-Results-from-Head-to-Head-Pharmacodynamic-Study-Comparing-OPNT003-Nasal-Nalmefene-to-Nasal-Naloxone.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone2022-04-27T20:01:00Z<![CDATA[SANTA MONICA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a pharmacodynamic (“PD”) study for OPNT003, nasal nalmefene, (3mg nalmefene hydrochloride), an investigational treatment for opioid overdose.]]>https://www.globenewswire.com/news-release/2022/03/15/2403886/0/en/Opiant-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=27210Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update2022-03-15T20:05:00Z<![CDATA[SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and provided a corporate update. Recent highlights include:]]>